NPPA slaps ₹6.32 lakh penalty on Torrent Pharma for Drug Pricing Violation, shares in green 

BL Mumbai Bureau Updated - October 18, 2024 at 07:09 PM.

Torrent Pharmaceuticals stated that the order would not have any material financial impact on the company’s operations

The National Pharmaceutical Pricing Authority (NPPA) has issued a demand notice to Torrent Pharmaceuticals Limited for launching a new drug without prior price approval, imposing a penalty of ₹6,32,689. The notice, dated October 17, 2024, was issued under paragraph 15 of the Drug Price Control Order 2013.

The shares of Torrent Pharmaceuticals Limited were trading at ₹3,446 up by ₹49.35 or 1.45 per cent on the NSE towards the closing bell.

The Ahmedabad-based pharmaceutical company disclosed this development in a regulatory filing to the stock exchanges on October 18. According to the filing, the violation pertains to the launch of a new drug for which the company obtained price approval after the product was already in the market.

Torrent Pharmaceuticals stated that the order would not have any material financial impact on the company’s operations. The notice was issued by the NPPA Director from their office at YMCA Cultural Center Building in New Delhi.

Published on October 18, 2024 13:39

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.